nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA1—hematopoietic system—malaria	0.0244	0.0748	CbGeAlD
Lithium—IMPA1—kidney—malaria	0.02	0.0613	CbGeAlD
Lithium—IMPA2—saliva-secreting gland—malaria	0.0192	0.0588	CbGeAlD
Lithium—Dystonia—Quinine—malaria	0.0187	0.0368	CcSEcCtD
Lithium—Dystonia—Quinidine—malaria	0.0187	0.0368	CcSEcCtD
Lithium—GSK3B—hematopoietic system—malaria	0.018	0.0551	CbGeAlD
Lithium—Optic atrophy—Quinine—malaria	0.0169	0.0333	CcSEcCtD
Lithium—Optic atrophy—Quinidine—malaria	0.0169	0.0333	CcSEcCtD
Lithium—Dystonia—Quinidine barbiturate—malaria	0.0169	0.0332	CcSEcCtD
Lithium—GSK3A—saliva-secreting gland—malaria	0.0164	0.0502	CbGeAlD
Lithium—IMPA1—blood—malaria	0.0162	0.0496	CbGeAlD
Lithium—Optic atrophy—Quinidine barbiturate—malaria	0.0153	0.0301	CcSEcCtD
Lithium—IMPA2—kidney—malaria	0.015	0.046	CbGeAlD
Lithium—GSK3B—kidney—malaria	0.0147	0.0451	CbGeAlD
Lithium—IMPA2—digestive system—malaria	0.0127	0.039	CbGeAlD
Lithium—IMPA1—liver—malaria	0.0126	0.0388	CbGeAlD
Lithium—GSK3B—digestive system—malaria	0.0125	0.0383	CbGeAlD
Lithium—Goitre—Sulfadiazine—malaria	0.0124	0.0245	CcSEcCtD
Lithium—IMPA2—blood—malaria	0.0121	0.0372	CbGeAlD
Lithium—Myasthenia gravis—Quinine—malaria	0.0121	0.0237	CcSEcCtD
Lithium—Myasthenia gravis—Quinidine—malaria	0.0121	0.0237	CcSEcCtD
Lithium—GSK3B—blood—malaria	0.0119	0.0365	CbGeAlD
Lithium—IMPA2—bone marrow—malaria	0.0117	0.036	CbGeAlD
Lithium—Myasthenia gravis—Quinidine barbiturate—malaria	0.0109	0.0214	CcSEcCtD
Lithium—GSK3A—digestive system—malaria	0.0109	0.0333	CbGeAlD
Lithium—GRIA3—liver—malaria	0.0107	0.033	CbGeAlD
Lithium—Taste metallic—Clindamycin—malaria	0.0104	0.0205	CcSEcCtD
Lithium—GSK3A—blood—malaria	0.0103	0.0317	CbGeAlD
Lithium—IMPA1—brain—malaria	0.01	0.0308	CbGeAlD
Lithium—GSK3A—bone marrow—malaria	0.01	0.0307	CbGeAlD
Lithium—IMPA2—liver—malaria	0.00949	0.0291	CbGeAlD
Lithium—GSK3B—liver—malaria	0.00931	0.0285	CbGeAlD
Lithium—GRIA3—brain—malaria	0.00853	0.0261	CbGeAlD
Lithium—Hyperthyroidism—Clindamycin—malaria	0.00837	0.0165	CcSEcCtD
Lithium—GSK3A—Leptin signaling pathway—CISH—malaria	0.00832	0.0503	CbGpPWpGaD
Lithium—GSK3A—liver—malaria	0.00809	0.0248	CbGeAlD
Lithium—IMPA2—brain—malaria	0.00753	0.0231	CbGeAlD
Lithium—GSK3B—brain—malaria	0.00739	0.0226	CbGeAlD
Lithium—GSK3A—brain—malaria	0.00642	0.0197	CbGeAlD
Lithium—GSK3B—Leptin signaling pathway—CISH—malaria	0.00615	0.0371	CbGpPWpGaD
Lithium—Blindness—Quinidine—malaria	0.00586	0.0115	CcSEcCtD
Lithium—Blindness—Quinine—malaria	0.00586	0.0115	CcSEcCtD
Lithium—GSK3A—T-Cell Receptor and Co-stimulatory Signaling—CD8A—malaria	0.00578	0.0349	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—CISH—malaria	0.00562	0.0339	CbGpPWpGaD
Lithium—Blindness—Quinidine barbiturate—malaria	0.00529	0.0104	CcSEcCtD
Lithium—Optic neuritis—Quinine—malaria	0.00528	0.0104	CcSEcCtD
Lithium—Optic neuritis—Quinidine—malaria	0.00528	0.0104	CcSEcCtD
Lithium—Folliculitis—Clindamycin—malaria	0.00526	0.0104	CcSEcCtD
Lithium—Oliguria—Sulfadiazine—malaria	0.00482	0.00949	CcSEcCtD
Lithium—Optic neuritis—Quinidine barbiturate—malaria	0.00476	0.00937	CcSEcCtD
Lithium—Albuminuria—Dapsone—malaria	0.00458	0.00902	CcSEcCtD
Lithium—GSK3A—SREBP signalling—SCARB1—malaria	0.00435	0.0262	CbGpPWpGaD
Lithium—Scotoma—Quinidine—malaria	0.00428	0.00841	CcSEcCtD
Lithium—Scotoma—Quinine—malaria	0.00428	0.00841	CcSEcCtD
Lithium—GSK3B—T-Cell Receptor and Co-stimulatory Signaling—CD8A—malaria	0.00427	0.0258	CbGpPWpGaD
Lithium—Nystagmus—Quinidine barbiturate—malaria	0.0041	0.00807	CcSEcCtD
Lithium—Scotoma—Quinidine barbiturate—malaria	0.00386	0.00759	CcSEcCtD
Lithium—Scotoma—Pentoxifylline—malaria	0.00385	0.00758	CcSEcCtD
Lithium—Polyuria—Sulfadiazine—malaria	0.00367	0.00723	CcSEcCtD
Lithium—Oliguria—Clindamycin—malaria	0.00359	0.00707	CcSEcCtD
Lithium—Oliguria—Quinidine—malaria	0.00352	0.00693	CcSEcCtD
Lithium—Oliguria—Quinine—malaria	0.00352	0.00693	CcSEcCtD
Lithium—Leukocytosis—Clindamycin—malaria	0.00352	0.00693	CcSEcCtD
Lithium—Hallucination—Proguanil—malaria	0.00335	0.00658	CcSEcCtD
Lithium—Oliguria—Quinidine barbiturate—malaria	0.00318	0.00626	CcSEcCtD
Lithium—GSK3A—T-Cell Receptor and Co-stimulatory Signaling—IL2—malaria	0.00306	0.0185	CbGpPWpGaD
Lithium—Ataxia—Sulfadiazine—malaria	0.00303	0.00597	CcSEcCtD
Lithium—Coma—Quinine—malaria	0.00297	0.00584	CcSEcCtD
Lithium—Coma—Quinidine—malaria	0.00297	0.00584	CcSEcCtD
Lithium—Anorexia—Pyrimethamine—malaria	0.00292	0.00575	CcSEcCtD
Lithium—Salivary hypersecretion—Pentoxifylline—malaria	0.00284	0.00559	CcSEcCtD
Lithium—Depressed level of consciousness—Quinidine barbiturate—malaria	0.00283	0.00557	CcSEcCtD
Lithium—Swelling—Clindamycin—malaria	0.00272	0.00536	CcSEcCtD
Lithium—Coma—Quinidine barbiturate—malaria	0.00268	0.00527	CcSEcCtD
Lithium—Decreased appetite—Pyrimethamine—malaria	0.00267	0.00524	CcSEcCtD
Lithium—IMPA2—Metabolism—DHODH—malaria	0.00265	0.016	CbGpPWpGaD
Lithium—GSK3B—IL-6 signaling pathway—CRP—malaria	0.00265	0.016	CbGpPWpGaD
Lithium—Swelling—Pentoxifylline—malaria	0.00241	0.00474	CcSEcCtD
Lithium—IMPA1—Metabolism—DHODH—malaria	0.00236	0.0143	CbGpPWpGaD
Lithium—GSK3A—IL-5 Signaling Pathway—IL2—malaria	0.00236	0.0143	CbGpPWpGaD
Lithium—Anorexia—Proguanil—malaria	0.00228	0.00448	CcSEcCtD
Lithium—GSK3B—T-Cell Receptor and Co-stimulatory Signaling—IL2—malaria	0.00226	0.0136	CbGpPWpGaD
Lithium—IMPA2—Metabolism—SLC4A1—malaria	0.00226	0.0136	CbGpPWpGaD
Lithium—Thirst—Pentoxifylline—malaria	0.00223	0.00439	CcSEcCtD
Lithium—Hallucination—Sulfadiazine—malaria	0.00222	0.00437	CcSEcCtD
Lithium—Ataxia—Quinine—malaria	0.00222	0.00436	CcSEcCtD
Lithium—Ataxia—Quinidine—malaria	0.00222	0.00436	CcSEcCtD
Lithium—Dry skin—Clindamycin—malaria	0.0022	0.00433	CcSEcCtD
Lithium—Muscular weakness—Dapsone—malaria	0.00219	0.00431	CcSEcCtD
Lithium—Lethargy—Quinidine barbiturate—malaria	0.00217	0.00427	CcSEcCtD
Lithium—GSK3B—Cardiac Progenitor Differentiation—KDR—malaria	0.00215	0.013	CbGpPWpGaD
Lithium—IMPA2—Metabolism—DECR1—malaria	0.00212	0.0128	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—HPGDS—malaria	0.0021	0.0127	CbGpPWpGaD
Lithium—Tinnitus—Sulfadiazine—malaria	0.00208	0.00409	CcSEcCtD
Lithium—Muscular weakness—Quinine—malaria	0.00208	0.00409	CcSEcCtD
Lithium—Muscular weakness—Quinidine—malaria	0.00208	0.00409	CcSEcCtD
Lithium—Decreased appetite—Proguanil—malaria	0.00208	0.00409	CcSEcCtD
Lithium—IMPA1—Metabolism—SLC4A1—malaria	0.00201	0.0121	CbGpPWpGaD
Lithium—Ataxia—Quinidine barbiturate—malaria	0.002	0.00394	CcSEcCtD
Lithium—Gastrointestinal pain—Proguanil—malaria	0.00195	0.00384	CcSEcCtD
Lithium—Vomiting—Pyrimethamine—malaria	0.00195	0.00384	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—NANP—malaria	0.00194	0.0117	CbGpPWpGaD
Lithium—IMPA2—Metabolism—HBB—malaria	0.00192	0.0116	CbGpPWpGaD
Lithium—IMPA1—Metabolism—DECR1—malaria	0.00189	0.0114	CbGpPWpGaD
Lithium—Abdominal pain—Proguanil—malaria	0.00189	0.00372	CcSEcCtD
Lithium—Body temperature increased—Proguanil—malaria	0.00189	0.00372	CcSEcCtD
Lithium—Muscular weakness—Quinidine barbiturate—malaria	0.00188	0.00369	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL4—malaria	0.00183	0.0111	CbGpPWpGaD
Lithium—GSK3B—IL-5 Signaling Pathway—IL2—malaria	0.00175	0.0105	CbGpPWpGaD
Lithium—Vertigo—Sulfadiazine—malaria	0.00175	0.00343	CcSEcCtD
Lithium—GSK3B—Alzheimers Disease—FAS—malaria	0.00174	0.0105	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—IL18—malaria	0.00172	0.0104	CbGpPWpGaD
Lithium—IMPA1—Metabolism—HBB—malaria	0.00171	0.0103	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PKLR—malaria	0.00171	0.0103	CbGpPWpGaD
Lithium—Convulsion—Sulfadiazine—malaria	0.00168	0.00331	CcSEcCtD
Lithium—Bradycardia—Quinidine—malaria	0.00166	0.00327	CcSEcCtD
Lithium—Bradycardia—Quinine—malaria	0.00166	0.00327	CcSEcCtD
Lithium—Arthralgia—Sulfadiazine—malaria	0.00165	0.00325	CcSEcCtD
Lithium—Drowsiness—Quinidine barbiturate—malaria	0.00164	0.00323	CcSEcCtD
Lithium—Drowsiness—Pentoxifylline—malaria	0.00164	0.00322	CcSEcCtD
Lithium—Diarrhoea—Proguanil—malaria	0.00163	0.00322	CcSEcCtD
Lithium—Tinnitus—Dapsone—malaria	0.0016	0.00315	CcSEcCtD
Lithium—IMPA1—Metabolism—PKLR—malaria	0.00152	0.0092	CbGpPWpGaD
Lithium—IMPA2—Metabolism—G6PD—malaria	0.00152	0.0092	CbGpPWpGaD
Lithium—Tinnitus—Quinine—malaria	0.00152	0.00299	CcSEcCtD
Lithium—Tinnitus—Quinidine—malaria	0.00152	0.00299	CcSEcCtD
Lithium—Vomiting—Proguanil—malaria	0.00152	0.00299	CcSEcCtD
Lithium—Anorexia—Sulfadiazine—malaria	0.00151	0.00297	CcSEcCtD
Lithium—Rash—Proguanil—malaria	0.00151	0.00296	CcSEcCtD
Lithium—Dermatitis—Proguanil—malaria	0.0015	0.00296	CcSEcCtD
Lithium—Bradycardia—Quinidine barbiturate—malaria	0.0015	0.00295	CcSEcCtD
Lithium—Headache—Proguanil—malaria	0.0015	0.00294	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—FCGR2B—malaria	0.00148	0.00891	CbGpPWpGaD
Lithium—Hallucination—Quinidine barbiturate—malaria	0.00146	0.00288	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—ICAM1—malaria	0.00145	0.00878	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Sulfadiazine—malaria	0.00144	0.00284	CcSEcCtD
Lithium—GSK3A—Leptin signaling pathway—IL1B—malaria	0.00143	0.00866	CbGpPWpGaD
Lithium—Flatulence—Clindamycin—malaria	0.00143	0.00281	CcSEcCtD
Lithium—Nausea—Proguanil—malaria	0.00142	0.00279	CcSEcCtD
Lithium—Dysgeusia—Clindamycin—malaria	0.00142	0.00279	CcSEcCtD
Lithium—Vision blurred—Dapsone—malaria	0.00141	0.00277	CcSEcCtD
Lithium—GSK3B—Corticotropin-releasing hormone—TLR4—malaria	0.00138	0.00836	CbGpPWpGaD
Lithium—Decreased appetite—Sulfadiazine—malaria	0.00138	0.00271	CcSEcCtD
Lithium—Tinnitus—Quinidine barbiturate—malaria	0.00137	0.0027	CcSEcCtD
Lithium—GSK3A—Innate Immune System—TIRAP—malaria	0.00137	0.00827	CbGpPWpGaD
Lithium—IMPA1—Metabolism—G6PD—malaria	0.00136	0.0082	CbGpPWpGaD
Lithium—Vertigo—Dapsone—malaria	0.00134	0.00264	CcSEcCtD
Lithium—Vision blurred—Quinine—malaria	0.00134	0.00263	CcSEcCtD
Lithium—Vision blurred—Quinidine—malaria	0.00134	0.00263	CcSEcCtD
Lithium—Tremor—Quinine—malaria	0.00133	0.00262	CcSEcCtD
Lithium—Tremor—Quinidine—malaria	0.00133	0.00262	CcSEcCtD
Lithium—Arrhythmia—Pentoxifylline—malaria	0.00131	0.00258	CcSEcCtD
Lithium—GSK3A—DAP12 interactions—HLA-B—malaria	0.00131	0.00791	CbGpPWpGaD
Lithium—Agitation—Quinidine—malaria	0.0013	0.00257	CcSEcCtD
Lithium—Agitation—Quinine—malaria	0.0013	0.00257	CcSEcCtD
Lithium—Vertigo—Clindamycin—malaria	0.0013	0.00256	CcSEcCtD
Lithium—Angioedema—Quinidine—malaria	0.0013	0.00255	CcSEcCtD
Lithium—Angioedema—Quinine—malaria	0.0013	0.00255	CcSEcCtD
Lithium—Gastrointestinal pain—Sulfadiazine—malaria	0.0013	0.00255	CcSEcCtD
Lithium—Vertigo—Quinidine—malaria	0.00128	0.00251	CcSEcCtD
Lithium—Vertigo—Quinine—malaria	0.00128	0.00251	CcSEcCtD
Lithium—GSK3A—Innate Immune System—CR1—malaria	0.00127	0.00769	CbGpPWpGaD
Lithium—Syncope—Quinidine—malaria	0.00127	0.0025	CcSEcCtD
Lithium—Syncope—Quinine—malaria	0.00127	0.0025	CcSEcCtD
Lithium—Flatulence—Pentoxifylline—malaria	0.00126	0.00248	CcSEcCtD
Lithium—Abdominal pain—Sulfadiazine—malaria	0.00125	0.00247	CcSEcCtD
Lithium—Body temperature increased—Sulfadiazine—malaria	0.00125	0.00247	CcSEcCtD
Lithium—Dysgeusia—Pentoxifylline—malaria	0.00125	0.00246	CcSEcCtD
Lithium—Loss of consciousness—Quinidine—malaria	0.00125	0.00245	CcSEcCtD
Lithium—Loss of consciousness—Quinine—malaria	0.00125	0.00245	CcSEcCtD
Lithium—Convulsion—Quinidine—malaria	0.00123	0.00242	CcSEcCtD
Lithium—Convulsion—Quinine—malaria	0.00123	0.00242	CcSEcCtD
Lithium—GSK3B—TWEAK Signaling Pathway—TNF—malaria	0.00122	0.00739	CbGpPWpGaD
Lithium—Discomfort—Clindamycin—malaria	0.00122	0.00239	CcSEcCtD
Lithium—Vision blurred—Quinidine barbiturate—malaria	0.00121	0.00238	CcSEcCtD
Lithium—Vision blurred—Pentoxifylline—malaria	0.0012	0.00237	CcSEcCtD
Lithium—Tremor—Quinidine barbiturate—malaria	0.0012	0.00236	CcSEcCtD
Lithium—Tremor—Pentoxifylline—malaria	0.0012	0.00236	CcSEcCtD
Lithium—Agitation—Quinidine barbiturate—malaria	0.00118	0.00232	CcSEcCtD
Lithium—Agitation—Pentoxifylline—malaria	0.00117	0.00231	CcSEcCtD
Lithium—Angioedema—Quinidine barbiturate—malaria	0.00117	0.0023	CcSEcCtD
Lithium—Angioedema—Pentoxifylline—malaria	0.00117	0.0023	CcSEcCtD
Lithium—Confusional state—Quinidine—malaria	0.00117	0.0023	CcSEcCtD
Lithium—Confusional state—Quinine—malaria	0.00117	0.0023	CcSEcCtD
Lithium—IMPA2—Metabolism—HPGDS—malaria	0.00116	0.00702	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—FAS—malaria	0.00116	0.00701	CbGpPWpGaD
Lithium—Oedema—Quinidine—malaria	0.00116	0.00228	CcSEcCtD
Lithium—Oedema—Quinine—malaria	0.00116	0.00228	CcSEcCtD
Lithium—Vertigo—Quinidine barbiturate—malaria	0.00115	0.00226	CcSEcCtD
Lithium—Syncope—Quinidine barbiturate—malaria	0.00115	0.00226	CcSEcCtD
Lithium—Shock—Quinidine—malaria	0.00114	0.00224	CcSEcCtD
Lithium—Shock—Quinine—malaria	0.00114	0.00224	CcSEcCtD
Lithium—Loss of consciousness—Quinidine barbiturate—malaria	0.00113	0.00222	CcSEcCtD
Lithium—Convulsion—Quinidine barbiturate—malaria	0.00111	0.00218	CcSEcCtD
Lithium—Convulsion—Pentoxifylline—malaria	0.00111	0.00218	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IFNG—malaria	0.00111	0.00668	CbGpPWpGaD
Lithium—Anorexia—Quinine—malaria	0.0011	0.00217	CcSEcCtD
Lithium—Anorexia—Quinidine—malaria	0.0011	0.00217	CcSEcCtD
Lithium—Hypotension—Clindamycin—malaria	0.0011	0.00217	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—FCGR2B—malaria	0.00109	0.00658	CbGpPWpGaD
Lithium—Arthralgia—Quinidine barbiturate—malaria	0.00109	0.00215	CcSEcCtD
Lithium—Diarrhoea—Sulfadiazine—malaria	0.00108	0.00213	CcSEcCtD
Lithium—GSK3A—Innate Immune System—TLR9—malaria	0.00108	0.00654	CbGpPWpGaD
Lithium—Hypotension—Quinine—malaria	0.00108	0.00213	CcSEcCtD
Lithium—Hypotension—Quinidine—malaria	0.00108	0.00213	CcSEcCtD
Lithium—IMPA2—Metabolism—DHFR—malaria	0.00108	0.00651	CbGpPWpGaD
Lithium—Discomfort—Pentoxifylline—malaria	0.00108	0.00212	CcSEcCtD
Lithium—IMPA2—Metabolism—SCARB1—malaria	0.00107	0.00644	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PKLR—malaria	0.00107	0.00643	CbGpPWpGaD
Lithium—Dry mouth—Pentoxifylline—malaria	0.00106	0.00209	CcSEcCtD
Lithium—GSK3B—Leptin signaling pathway—IL1B—malaria	0.00106	0.0064	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Quinine—malaria	0.00106	0.00208	CcSEcCtD
Lithium—Musculoskeletal discomfort—Quinidine—malaria	0.00106	0.00208	CcSEcCtD
Lithium—Confusional state—Quinidine barbiturate—malaria	0.00105	0.00207	CcSEcCtD
Lithium—Confusional state—Pentoxifylline—malaria	0.00105	0.00207	CcSEcCtD
Lithium—Oedema—Quinidine barbiturate—malaria	0.00105	0.00206	CcSEcCtD
Lithium—Oedema—Pentoxifylline—malaria	0.00104	0.00205	CcSEcCtD
Lithium—Dyspepsia—Clindamycin—malaria	0.00104	0.00205	CcSEcCtD
Lithium—IMPA1—Metabolism—HPGDS—malaria	0.00104	0.00625	CbGpPWpGaD
Lithium—Shock—Quinidine barbiturate—malaria	0.00103	0.00202	CcSEcCtD
Lithium—Shock—Pentoxifylline—malaria	0.00103	0.00202	CcSEcCtD
Lithium—Fatigue—Clindamycin—malaria	0.00102	0.002	CcSEcCtD
Lithium—GSK3B—Alzheimers Disease—IL1B—malaria	0.00102	0.00614	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TIRAP—malaria	0.00101	0.00611	CbGpPWpGaD
Lithium—Vomiting—Sulfadiazine—malaria	0.00101	0.00198	CcSEcCtD
Lithium—Decreased appetite—Quinidine—malaria	0.00101	0.00198	CcSEcCtD
Lithium—Decreased appetite—Quinine—malaria	0.00101	0.00198	CcSEcCtD
Lithium—Rash—Sulfadiazine—malaria	0.001	0.00197	CcSEcCtD
Lithium—Dermatitis—Sulfadiazine—malaria	0.000999	0.00197	CcSEcCtD
Lithium—Gastrointestinal pain—Dapsone—malaria	0.000998	0.00196	CcSEcCtD
Lithium—Anorexia—Quinidine barbiturate—malaria	0.000996	0.00196	CcSEcCtD
Lithium—Anorexia—Pentoxifylline—malaria	0.000995	0.00196	CcSEcCtD
Lithium—Headache—Sulfadiazine—malaria	0.000993	0.00195	CcSEcCtD
Lithium—GSK3B—TWEAK Signaling Pathway—IL6—malaria	0.000987	0.00596	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—TNF—malaria	0.000986	0.00595	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL2—malaria	0.000984	0.00594	CbGpPWpGaD
Lithium—Hypotension—Quinidine barbiturate—malaria	0.000977	0.00192	CcSEcCtD
Lithium—Hypotension—Pentoxifylline—malaria	0.000975	0.00192	CcSEcCtD
Lithium—GSK3B—IL-6 signaling pathway—IL6—malaria	0.000969	0.00585	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HLA-B—malaria	0.000967	0.00584	CbGpPWpGaD
Lithium—Gastrointestinal pain—Clindamycin—malaria	0.000965	0.0019	CcSEcCtD
Lithium—Abdominal pain—Dapsone—malaria	0.000965	0.0019	CcSEcCtD
Lithium—Body temperature increased—Dapsone—malaria	0.000965	0.0019	CcSEcCtD
Lithium—IMPA1—Metabolism—DHFR—malaria	0.000961	0.0058	CbGpPWpGaD
Lithium—Feeling abnormal—Quinine—malaria	0.000954	0.00188	CcSEcCtD
Lithium—Feeling abnormal—Quinidine—malaria	0.000954	0.00188	CcSEcCtD
Lithium—Musculoskeletal discomfort—Quinidine barbiturate—malaria	0.000952	0.00187	CcSEcCtD
Lithium—IMPA1—Metabolism—SCARB1—malaria	0.000951	0.00574	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Pentoxifylline—malaria	0.000951	0.00187	CcSEcCtD
Lithium—GSK3A—Immune System—CISH—malaria	0.000948	0.00572	CbGpPWpGaD
Lithium—Gastrointestinal pain—Quinine—malaria	0.000947	0.00186	CcSEcCtD
Lithium—Gastrointestinal pain—Quinidine—malaria	0.000947	0.00186	CcSEcCtD
Lithium—Nausea—Sulfadiazine—malaria	0.000942	0.00185	CcSEcCtD
Lithium—GSK3B—Innate Immune System—CR1—malaria	0.000941	0.00568	CbGpPWpGaD
Lithium—Body temperature increased—Clindamycin—malaria	0.000933	0.00184	CcSEcCtD
Lithium—Abdominal pain—Clindamycin—malaria	0.000933	0.00184	CcSEcCtD
Lithium—Somnolence—Quinidine barbiturate—malaria	0.000929	0.00183	CcSEcCtD
Lithium—Somnolence—Pentoxifylline—malaria	0.000928	0.00183	CcSEcCtD
Lithium—Dyspepsia—Pentoxifylline—malaria	0.000918	0.00181	CcSEcCtD
Lithium—Abdominal pain—Quinidine—malaria	0.000916	0.0018	CcSEcCtD
Lithium—Body temperature increased—Quinidine—malaria	0.000916	0.0018	CcSEcCtD
Lithium—Abdominal pain—Quinine—malaria	0.000916	0.0018	CcSEcCtD
Lithium—Body temperature increased—Quinine—malaria	0.000916	0.0018	CcSEcCtD
Lithium—Decreased appetite—Quinidine barbiturate—malaria	0.000909	0.00179	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IFNG—malaria	0.000908	0.00548	CbGpPWpGaD
Lithium—Decreased appetite—Pentoxifylline—malaria	0.000907	0.00178	CcSEcCtD
Lithium—GSK3B—Corticotropin-releasing hormone—IL2—malaria	0.000897	0.00542	CbGpPWpGaD
Lithium—GSK3A—Immune System—FCGR2B—malaria	0.000895	0.0054	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—FCGR2A—malaria	0.000866	0.00523	CbGpPWpGaD
Lithium—Feeling abnormal—Quinidine barbiturate—malaria	0.000861	0.0017	CcSEcCtD
Lithium—Feeling abnormal—Pentoxifylline—malaria	0.00086	0.00169	CcSEcCtD
Lithium—Gastrointestinal pain—Quinidine barbiturate—malaria	0.000855	0.00168	CcSEcCtD
Lithium—Gastrointestinal pain—Pentoxifylline—malaria	0.000853	0.00168	CcSEcCtD
Lithium—Asthenia—Clindamycin—malaria	0.000847	0.00167	CcSEcCtD
Lithium—Asthenia—Quinine—malaria	0.000831	0.00164	CcSEcCtD
Lithium—Asthenia—Quinidine—malaria	0.000831	0.00164	CcSEcCtD
Lithium—Abdominal pain—Quinidine barbiturate—malaria	0.000826	0.00163	CcSEcCtD
Lithium—Body temperature increased—Quinidine barbiturate—malaria	0.000826	0.00163	CcSEcCtD
Lithium—Abdominal pain—Pentoxifylline—malaria	0.000825	0.00162	CcSEcCtD
Lithium—Body temperature increased—Pentoxifylline—malaria	0.000825	0.00162	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—FAS—malaria	0.000824	0.00497	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL1B—malaria	0.00081	0.00489	CbGpPWpGaD
Lithium—Diarrhoea—Clindamycin—malaria	0.000808	0.00159	CcSEcCtD
Lithium—GSK3B—Innate Immune System—TLR9—malaria	0.0008	0.00483	CbGpPWpGaD
Lithium—GSK3A—Immune System—TIRAP—malaria	0.000798	0.00482	CbGpPWpGaD
Lithium—Diarrhoea—Quinine—malaria	0.000793	0.00156	CcSEcCtD
Lithium—Diarrhoea—Quinidine—malaria	0.000793	0.00156	CcSEcCtD
Lithium—Dizziness—Clindamycin—malaria	0.000781	0.00154	CcSEcCtD
Lithium—Vomiting—Dapsone—malaria	0.000776	0.00153	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—KDR—malaria	0.000775	0.00468	CbGpPWpGaD
Lithium—Dizziness—Quinidine—malaria	0.000766	0.00151	CcSEcCtD
Lithium—Dizziness—Quinine—malaria	0.000766	0.00151	CcSEcCtD
Lithium—Headache—Dapsone—malaria	0.000765	0.0015	CcSEcCtD
Lithium—Vomiting—Clindamycin—malaria	0.000751	0.00148	CcSEcCtD
Lithium—Asthenia—Quinidine barbiturate—malaria	0.00075	0.00148	CcSEcCtD
Lithium—Asthenia—Pentoxifylline—malaria	0.000749	0.00147	CcSEcCtD
Lithium—Rash—Clindamycin—malaria	0.000744	0.00146	CcSEcCtD
Lithium—Dermatitis—Clindamycin—malaria	0.000744	0.00146	CcSEcCtD
Lithium—GSK3A—Immune System—CR1—malaria	0.000742	0.00448	CbGpPWpGaD
Lithium—Headache—Clindamycin—malaria	0.00074	0.00146	CcSEcCtD
Lithium—GSK3B—Alzheimers Disease—TNF—malaria	0.000738	0.00446	CbGpPWpGaD
Lithium—Vomiting—Quinidine—malaria	0.000736	0.00145	CcSEcCtD
Lithium—Vomiting—Quinine—malaria	0.000736	0.00145	CcSEcCtD
Lithium—Rash—Quinine—malaria	0.00073	0.00144	CcSEcCtD
Lithium—Rash—Quinidine—malaria	0.00073	0.00144	CcSEcCtD
Lithium—Dermatitis—Quinidine—malaria	0.00073	0.00144	CcSEcCtD
Lithium—Dermatitis—Quinine—malaria	0.00073	0.00144	CcSEcCtD
Lithium—Headache—Quinidine—malaria	0.000726	0.00143	CcSEcCtD
Lithium—Headache—Quinine—malaria	0.000726	0.00143	CcSEcCtD
Lithium—Nausea—Dapsone—malaria	0.000725	0.00143	CcSEcCtD
Lithium—Diarrhoea—Quinidine barbiturate—malaria	0.000715	0.00141	CcSEcCtD
Lithium—Diarrhoea—Pentoxifylline—malaria	0.000714	0.0014	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—NOS2—malaria	0.000704	0.00425	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—malaria	0.000703	0.00424	CbGpPWpGaD
Lithium—Nausea—Clindamycin—malaria	0.000701	0.00138	CcSEcCtD
Lithium—GSK3B—Immune System—CISH—malaria	0.0007	0.00423	CbGpPWpGaD
Lithium—Dizziness—Quinidine barbiturate—malaria	0.000691	0.00136	CcSEcCtD
Lithium—Dizziness—Pentoxifylline—malaria	0.00069	0.00136	CcSEcCtD
Lithium—Nausea—Quinidine—malaria	0.000688	0.00135	CcSEcCtD
Lithium—Nausea—Quinine—malaria	0.000688	0.00135	CcSEcCtD
Lithium—GSK3A—Disease—PKLR—malaria	0.000685	0.00413	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CD36—malaria	0.000669	0.00404	CbGpPWpGaD
Lithium—Vomiting—Quinidine barbiturate—malaria	0.000665	0.00131	CcSEcCtD
Lithium—Vomiting—Pentoxifylline—malaria	0.000663	0.00131	CcSEcCtD
Lithium—GSK3B—Immune System—FCGR2B—malaria	0.000661	0.00399	CbGpPWpGaD
Lithium—Rash—Quinidine barbiturate—malaria	0.000659	0.0013	CcSEcCtD
Lithium—Dermatitis—Quinidine barbiturate—malaria	0.000658	0.0013	CcSEcCtD
Lithium—Rash—Pentoxifylline—malaria	0.000658	0.00129	CcSEcCtD
Lithium—Dermatitis—Pentoxifylline—malaria	0.000657	0.00129	CcSEcCtD
Lithium—Headache—Quinidine barbiturate—malaria	0.000655	0.00129	CcSEcCtD
Lithium—Headache—Pentoxifylline—malaria	0.000654	0.00129	CcSEcCtD
Lithium—GSK3B—Innate Immune System—FCGR2A—malaria	0.00064	0.00386	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR9—malaria	0.000631	0.00381	CbGpPWpGaD
Lithium—Nausea—Quinidine barbiturate—malaria	0.000621	0.00122	CcSEcCtD
Lithium—Nausea—Pentoxifylline—malaria	0.00062	0.00122	CcSEcCtD
Lithium—GSK3A—Disease—G6PD—malaria	0.00061	0.00369	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CD36—malaria	0.000597	0.0036	CbGpPWpGaD
Lithium—GSK3B—Immune System—TIRAP—malaria	0.00059	0.00356	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL6—malaria	0.000578	0.00349	CbGpPWpGaD
Lithium—GSK3B—Immune System—CR1—malaria	0.000548	0.00331	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD40LG—malaria	0.000514	0.0031	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HLA-B—malaria	0.000509	0.00307	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD8A—malaria	0.000508	0.00307	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—IL6—malaria	0.000507	0.00306	CbGpPWpGaD
Lithium—GSK3B—Disease—PKLR—malaria	0.000506	0.00306	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ACKR1—malaria	0.000506	0.00305	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KDR—malaria	0.000505	0.00305	CbGpPWpGaD
Lithium—GSK3A—Immune System—FCGR2A—malaria	0.000504	0.00304	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD36—malaria	0.000499	0.00301	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—malaria	0.000493	0.00298	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-B—malaria	0.000488	0.00295	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—IL6—malaria	0.000485	0.00293	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD36—malaria	0.000479	0.00289	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—IL6—malaria	0.000477	0.00288	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL6—malaria	0.000474	0.00286	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR9—malaria	0.000466	0.00281	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—IL6—malaria	0.000456	0.00275	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—IL6—malaria	0.000454	0.00274	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—IL6—malaria	0.000452	0.00273	CbGpPWpGaD
Lithium—GSK3B—Disease—G6PD—malaria	0.000451	0.00272	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CRP—malaria	0.00045	0.00271	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—IL6—malaria	0.000449	0.00271	CbGpPWpGaD
Lithium—GSK3A—Disease—DHFR—malaria	0.000432	0.00261	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TLR4—malaria	0.000431	0.0026	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—IL6—malaria	0.000423	0.00255	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—IL6—malaria	0.000423	0.00255	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—IL6—malaria	0.000423	0.00255	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—IL6—malaria	0.000419	0.00253	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CD36—malaria	0.000417	0.00252	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—IL6—malaria	0.000415	0.00251	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—IL6—malaria	0.000413	0.0025	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TLR9—malaria	0.000408	0.00246	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ICAM1—malaria	0.000397	0.0024	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD40LG—malaria	0.000379	0.00229	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HLA-B—malaria	0.000376	0.00227	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD8A—malaria	0.000375	0.00227	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—IL6—malaria	0.000375	0.00226	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—IL6—malaria	0.000374	0.00226	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ACKR1—malaria	0.000374	0.00226	CbGpPWpGaD
Lithium—GSK3B—Immune System—FCGR2A—malaria	0.000373	0.00225	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD36—malaria	0.000369	0.00223	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-B—malaria	0.000361	0.00218	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KDR—malaria	0.000361	0.00218	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—IL6—malaria	0.000359	0.00216	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD36—malaria	0.000354	0.00214	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—IL6—malaria	0.000353	0.00213	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—IL6—malaria	0.000337	0.00203	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—IL6—malaria	0.000335	0.00202	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—IL6—malaria	0.000334	0.00201	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CRP—malaria	0.000332	0.00201	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—IL6—malaria	0.000332	0.002	CbGpPWpGaD
Lithium—GSK3B—Disease—DHFR—malaria	0.000319	0.00193	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR4—malaria	0.000319	0.00192	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL18—malaria	0.000313	0.00189	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—malaria	0.000312	0.00189	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—IL6—malaria	0.000312	0.00189	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—malaria	0.000312	0.00189	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD40LG—malaria	0.000311	0.00188	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—IL6—malaria	0.00031	0.00187	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—malaria	0.000308	0.00186	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—malaria	0.000307	0.00185	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—IL6—malaria	0.000305	0.00184	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD4—malaria	0.000304	0.00183	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TLR9—malaria	0.000301	0.00182	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-B—malaria	0.000296	0.00179	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ICAM1—malaria	0.000293	0.00177	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD4—malaria	0.000292	0.00176	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD36—malaria	0.00029	0.00175	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—IL6—malaria	0.000288	0.00174	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—malaria	0.000282	0.0017	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—malaria	0.000277	0.00167	CbGpPWpGaD
Lithium—GSK3A—Immune System—CRP—malaria	0.000262	0.00158	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR4—malaria	0.000251	0.00152	CbGpPWpGaD
Lithium—GSK3A—Immune System—ICAM1—malaria	0.000241	0.00145	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL18—malaria	0.000231	0.0014	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40LG—malaria	0.00023	0.00139	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—malaria	0.000228	0.00137	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—malaria	0.000227	0.00137	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD4—malaria	0.000224	0.00136	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—malaria	0.00022	0.00133	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-B—malaria	0.000219	0.00132	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD4—malaria	0.000216	0.0013	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD36—malaria	0.000215	0.0013	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—malaria	0.000213	0.00128	CbGpPWpGaD
Lithium—GSK3B—Immune System—CRP—malaria	0.000194	0.00117	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—malaria	0.000193	0.00116	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—malaria	0.000186	0.00112	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNG—malaria	0.000183	0.00111	CbGpPWpGaD
Lithium—GSK3B—Immune System—ICAM1—malaria	0.000178	0.00107	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—malaria	0.000177	0.00107	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—malaria	0.00017	0.00103	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—malaria	0.000164	0.000992	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—malaria	0.000163	0.000986	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—malaria	0.000163	0.000986	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—malaria	0.000163	0.000984	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—malaria	0.000163	0.000983	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—malaria	0.000162	0.00098	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—malaria	0.000137	0.00083	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNG—malaria	0.000135	0.000817	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—malaria	0.000131	0.000789	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—malaria	0.000121	0.000733	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—malaria	0.000121	0.000729	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—malaria	0.000121	0.000729	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—malaria	0.00012	0.000726	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—malaria	0.00012	0.000724	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—malaria	0.000105	0.000635	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—malaria	9.57e-05	0.000578	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—malaria	8.83e-05	0.000533	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—malaria	7.78e-05	0.00047	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—malaria	7.07e-05	0.000427	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—malaria	6.53e-05	0.000394	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—malaria	6.18e-05	0.000373	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—malaria	4.57e-05	0.000276	CbGpPWpGaD
